Pemetrexed
Product Images NDC 68001-537

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 68001-537). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Pemetrexed Fig1)

A Kaplan-Meier overall survival curve showing survival percentage over time in months. Two treatment arms are compared: P+P+C (black line) and P+C (gray line). Survival percentages decrease over approximately 21 months with the P+P+C arm showing higher survival rates. A table below the graph lists the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Pemetrexed For Injection 100mg Per Vial Label (Pemetrexed Fig10)

Pemetrexed for Injection, USP 100 mg per vial single-dose vial label from BluePoint Laboratories. The label includes usage instructions for intravenous use only, highlights it as a cytotoxic agent, and provides storage conditions. Manufacturer listed as Eugia Pharma Specialities Limited.*

FDA Label Image

Pemetrexed For Injection 100 Mf Per Vial Carton (Pemetrexed Fig11)

Packaging label for Pemetrexed for Injection, USP 100 mg per vial. The label indicates it is for intravenous use only and cautions that it is a cytotoxic agent. Manufactured for BluePoint Laboratories by Eugia Pharma Specialties Limited. The label includes instructions for reconstitution and storage, a barcode, and the NDC 68001-535-41.*

FDA Label Image

Pemetrexed For Injection 500mg Per Vial Label (Pemetrexed Fig12)

Pemetrexed for Injection, USP 500 mg per vial label from BluePoint Laboratories. The single-dose vial contains pemetrexed disodium equivalent to 500 mg pemetrexed with 500 mg mannitol. The label includes storage instructions and manufacturing details by Eugia Pharma Specialities Limited for BluePoint Laboratories. It features the NDC 68001-536-41 and a barcode.*

FDA Label Image

Pemetrexed For Injection 500mg Per Vial Carton (Pemetrexed Fig13)

The packaging label for Pemetrexed for Injection, USP, 500 mg per vial, a single-dose vial from BluePoint Laboratories. The label includes dosage details, storage instructions, and a caution noting it is a cytotoxic agent. Manufactured by Eugia Pharma Specialities Limited, India, the label also features an NDC number and barcode.*

FDA Label Image

Pemetrexed For Injection 1000mg Per Vial Label (Pemetrexed Fig14)

Label for Pemetrexed for Injection, USP 1,000 mg per vial by BluePoint Laboratories. The label states it is for intravenous use only and is a single-dose vial. It notes Pemetrexed disodium equivalent to 1,000 mg pemetrexed per vial and includes storage instructions and a caution regarding cytotoxicity.*

FDA Label Image

Pemetrexed For Injection 1000mg Vial Carton (Pemetrexed Fig15)

Packaging label for Pemetrexed for Injection, USP 1,000 mg per vial, single-dose vial by BluePoint Laboratories. The label includes storage instructions, dosage preparation details, and caution as a cytotoxic agent. Manufacturer is Eugia Pharma Specialities Limited, India, for BluePoint Laboratories.*

FDA Label Image

Figure 2 (Pemetrexed Fig2)

A survival curve chart comparing survival probability over 30 months for two treatment groups: Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). The chart includes patient risk numbers at various time points for both groups along the x-axis of survival time in months and y-axis of survival probability.*

FDA Label Image

Figure 3 (Pemetrexed Fig3)

A survival curve chart comparing survival probability over time in months for patients treated with Pemetrexed plus Cisplatin (PC) versus Gemcitabine plus Cisplatin (GC). The graph includes a number of patients at risk at various time points for both treatment groups.*

FDA Label Image

Figure 4 (Pemetrexed Fig4)

A Kaplan-Meier survival curve comparing survival probability over time (in months) between two treatment groups: Pemetrexed with Cisplatin and Gemcitabine with Cisplatin. The plot shows survival decreasing from 1.0 to near 0 over approximately 30 months, with a legend and number of patients at risk listed below the x-axis.*

FDA Label Image

Figure 5 (Pemetrexed Fig5)

A survival probability curve chart comparing Pemetrexed versus placebo over a duration of up to 42 months. The horizontal axis shows survival time in months, and the vertical axis shows survival probability. The chart includes patient risk counts at various time points for both Pemetrexed and placebo groups, illustrating survival trends over time.*

FDA Label Image

Figure 6 (Pemetrexed Fig6)

A Kaplan-Meier survival curve comparing survival probability over time in months for patients treated with Pemetrexed versus placebo. The solid line represents Pemetrexed, and the dotted line represents placebo, with a decreasing survival probability shown over approximately 42 months. A table below shows the number of patients at risk at specific time points for each group.*

FDA Label Image

Figure 7 (Pemetrexed Fig7)

A survival curve graph comparing the survival probability over time in months for patients treated with Pemetrexed versus placebo. The x-axis represents survival time in months, while the y-axis shows survival probability. A table below the graph lists the number of patients at risk at various time points for both treatment groups.*

FDA Label Image

Figure 8 (Pemetrexed Fig8)

A Kaplan-Meier survival curve comparing survival probability over time (months) between patients treated with Pemetrexed and those given a placebo. The graph includes a legend for Pemetrexed (solid line) and placebo (dotted line) and a table listing the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 9 (Pemetrexed Fig9)

A Kaplan-Meier survival curve comparing survival probability over time in months between two groups: one treated with Pemetrexed plus Cisplatin, and the other with Cisplatin alone. The graph includes a table below showing the number of patients at risk at different time points for each group.*

FDA Label Image

Chemical-structure (Pemetrexed Str)

Chemical structure of the active ingredient Pemetrexed, showing its molecular arrangement including rings and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.